Abstract
The role of the cholinergic system in schizophrenia remains controversial. A series of investigations are reviewed that describe the effects of pharmacological manipulation of the cholinergic system on schizophrenia symptomatology and whether putative measures of the cholinergic system are altered in schizophrenia. The effects of biperiden (an anticholinergic agent) on positive and negative symptoms of schizophrenia and on rapid eye movement (REM) latency and other sleep measures were assessed. Biperiden produced a significant increase in positive symptoms and a decrease in negative symptoms. REM latency was significantly shorter in schizophrenic patients and increased in both groups following biperiden. REM density decreased in a dose-dependent manner following biperiden in schizophrenic patients, but not in normal controls. The slope of REM density plotted against biperiden dose was inversely related to plasma homovanillic acid (HVA), an index of dopamine (DA) activity, in schizophrenic patients. These results further implicate the cholinergic system in schizophrenia pathophysiology and suggest a role for DA-acetylcholine (ACh) interactions in the production of sleep abnormalities and expression of positive and negative symptoms in schizophrenia.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
American Psychiatric Association. (1987): Diagnostic and Statistical Manual of Mental Disorders, 3rd ed., Revised (DSM-III-R). Washington DC: American Psychiatric Association.
Andreasen NC . (1983): Scale for the Assessment of Negative Symptoms (SANS). Iowa City: University of Iowa Press
Andreasen NC, Olsen S . (1982): Negative v positive schizophrenia: Definition and validation. Arch Gen Psychiat 39: 789–794
Angrist B, Rotrosen J, Gershon S . (1980): Differential effects of amphetamine and neuroleptics on negative vs. positive symptoms in schizophrenia. Psychopharmacology 72: 17–19
Avissar S, Schreiber G . (1989): Muscarinic receptor subclassification and G-proteins: Significance for lithium action in affective disorders and for the treatment of the extrapyramidal side-effects of neuroleptics. Biol Psychiat 26: 113–130
Berger M, Riemann D, Hochli D, Spiegel R . (1989): The cholinergic rapid eye movement sleep induction test with RS-86: State or trait marker of depression? Arch Gen Psychiat 46: 421–428
Bolden C, Cusack B, Richelson E . (1991): Clozapine is a potent and selective muscarinic antagonist at the five cloned human muscarinic acetylcholine receptors expressed in the CHO-K1 cells. Eur J Pharmacol 192: 205–206
Buchsbaum MS . (1990): The frontal lobes, basal ganglia, and temporal lobes as sites for schizophrenia. Schizophr Bull 16: 379–389
Carlsson M, Carlsson A . (1990): Interactions between glutamatergic and monoaminergic systems within the basal ganglia—Implications for schizophrenia and Parkinson's disease. TINS 13: 272–276
Carroll BJ, Greden JF, Haskett RF, Feinberg M, Albala AA, Martin FIR, Rubin RT, Heath B, Sharp PT, McLeod WL, McLeod MF . (1980): Neurotransmitter studies of neuroendocrine pathology in depression. Acta Psychiat Scand Suppl 61: 183–199
Chouinard G, Annable L, Mercier P, Turnier L . (1987): Long-term effects of L-dopa and procyclidine on neuroleptic-induced extrapyramidal and schizophrenic symptoms. Psychopharmacol Bull 23: 221–226
Cohen LH, Thale T, Tissenbaum MJ . (1944): Acetylcholine treatment of schizophrenia. Arch Neurol Psychiat 51: 171–175
Collard J, Lecoq R, Demaret A . (1946): Un essai de therapeutique pathogenique de la schizophrenei par un acetylcholinique: l'oxotremorine. Acta Neurological et Psychiatrica Belgica 65: 122–127
Crow TJ . (1980): Molecular pathology of schizophrenia: More than one disease process? Br Med J 280: 66–68
Damsma G, Robertson GS, Tham CS, Fibiger HC . (1991): Dopaminergic regulation of striatal acetylcholine release: Importance of D1 and N-methyl-D-aspartate receptors. J Pharmacol Exp Ther 259: 1064–1072
Davila R, Manero E, Zumarraga M, Andia I, Schweitzer JW, Friedhoff AJ . (1988): Plasma homovanillic acid as a predictor of response to neuroleptics. Arch Gen Psychiat 45: 564–567
Davis KL, Berger PA . (1978): Pharmacological investigations of the cholinergic imbalance hypotheses of movement disorders and psychosis. Biol Psychiat 13: 23–49
Davis KL, Hollister LE, Berger PA, Barchas JD . (1975): Cholinergic imbalance hypotheses of psychoses and movement disorders: Strategies for evaluation. Psychopharmacol Commun 1: 533–543
Davis KL, Hollister LE, Overall J, Johnson A, Train K . (1976): Physostigmine: Effects on cognition and affect in normal subjects. Psychopharmacology 51: 23–27
Docherty JP, van Kammen DP, Siris SG, Marder SR . (1978): Stages of onset of schizophrenic psychosis. Am J Psychiat 135: 420–426
Donlon P, Blacker K . (1973): Stages of schizophrenic decompensation and reintegration. J Nerv Ment Dis 157: 200–209
Douglass A, Bornstein R, Nino-Murcia G, Keenan S, Miles L, Zarcone V, Guilleminault C, Dement W . (1986): Creation of the ASDC sleep disorders questionnaire. Sleep Res 15: 117
Eltze M, Figala V . (1988): Affinity and selectivity of biperiden enantiomers for muscarinic receptor subtypes. Eur J Pharmacol 158: 11–19
Endicott J, Spitzer RL . (1978): A diagnostic interview: The schedule for affective disorders and schizophrenia. Arch Gen Psychiat 35: 837–844
Fayen M, Goldman MB, Moulthrop MA, Luchins DJ . (1988): Differential memory function with dopaminergic versus anticholinergic treatment of drug-induced extrapyramidal symptoms. Am J Psychiat 145: 483–486
Fisch RZ . (1987): Trihexyphenidyl abuse: Therapeutic implications for negative symptoms of schizophrenia. Acta Psychiat Scand 75: 91–94
Friedhoff AJ, Alpert M . (1973): A dopaminergic-cholinergic mechanism in production of psychotic symptoms. Biol Psychiat 6: 165–169
Gerlach J, Rasmussen PT, Hansen L, Kristjansen P . (1977): Antiparkinsonian agents and long-term neuroleptic treatment: Effect of G 31.406, orphenadrine, and placebo on parkinsonism, schizophrenic symptoms, depression, and anxiety. Acta Psychiat Scand 55: 251–260
Gillin JC, Sitaram N . (1984): Rapid eye movement (REM) sleep: Cholinergic mechanisms. Psychol Med 14: 501–506
Gillin JC, Post RM, Wyatt RJ, Goodwin FK, Snyder F, Bunney WE . (1973): REM inhibitory effect of L-dopa infusion during human sleep. Electroenceph Clin Neurophysiol 35: 181–186
Gillin JC, Sitaram N, Mendelson WB, Wyatt RJ . (1978): Physostigmine alters onset but not duration of REM sleep in man. Psychopharmacology 58: 111–114
Gillin JC, Sutton L, Ruiz C, Golshan S, Hirsch S, Warman C, Shiromani PJ . (1991): Dose-dependent inhibition of REM sleep in normal volunteers by biperiden, a muscarinic antagonist. Biol Psychiat 30: 151–156
Goff DC, Amico E, Dreyfuss D, Ciraulo D . (1994): A placebo-controlled trial of trihexyphenidyl in unmedicated patients with schizophrenia. Am J Psychiat 151: 429–431
Grimaldi R, Perucca E, Ruberto G, Gelmi C, Trimarchi F, Hollmann M, Crema A . (1986): Pharmacokinetic and pharmacodynamic differences following the intravenous and oral administration of the antiparkinson drug biperiden to normal subjects. Eur J Clin Pharmacol 29: 735–737
Guo N, Robertson GS, Fibiger HC . (1992): Scopolamine attenuates haloperidol-induced c-fos expression in the striatum. Brain Res 588: 164–167
Guy W . (1976): ECDEU Assessment Manual for Psychopharmacology, (DHEW Publication No. 76-338), National Institute of Mental Health, Rockville, MD
Haase H-J . (1965): The relationship of neuroleptic action to extrapyramidal phenomena. In Haase H-J, Janssen PAJ (eds), The Action of Neuroleptic Drugs. Amsterdam: North Holland Publishing Company, pp 56–103
Hedlund JL, Vieweg BW . (1980): The Brief Psychiatric Rating Scale (BPRS): A comprehensive review. J Operational Psychiat 11: 48–65
Hollmann M, Brode E, Greger G, Muller-Peltzer H, Wetzelsberger N . (1984): Biperiden effects and plasma levels in volunteers. Eur J Clin Pharmacol 27: 619–621
Horn AS, Coyle JT, Snyder SH . (1971): Catecholamine uptake by synaptosomes from rat brain. Structure-activity relationships of drugs with differential effects on dopamine and norepinephrine neurons. Mol Pharmacol 7: 66–80
Janowsky DS, El-Yousef MK, Davis JM, Sekerke HJ . (1972): A cholinergic-adrenergic hypothesis of mania and depression. Lancet 2: 632–635
Janowsky DS, El-Yousef MK, Davis JM, Sekerke HJ . (1973): Antagonistic effects of physostigmine and methylphenidate in man. Am J Psychiat 130: 1370–1376
Janowsky DS, Risch SC, Kennedy B, Ziegler M, Huey L . (1986): Central muscarinic effects on mood, cardiovascular function, pituitary and adrenal neuroendocrine release. Psychopharmacology 89: 150–154
Jibson MO, Tandon R . (1998): New atypical antipsychotic medications. J Psychiat Res 32: 215–228
Johnstone EC, Crow TJ, Ferrier IN, Frith CD, Owens DGC, Bourne RC, Gamble SJ . (1983): Adverse effects of anticholinergic medication on positive schizophrenic symptoms. Psycholog Med 13: 513–527
Johnstone EC, Crow TJ, Frith CD, Owens DG . (1988): The Northwick Park “functional” psychosis study: Diagnosis and treatment response. Lancet 2: 119–125
Kane JM, Honigfeld G, Singer J, Meltzer HY . (1988): Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine. Arch Gen Psychiat 45: 789–796
Maixner S, Tandon R, Douglass A, Shipley JE, Decker L, Goldman M . (1996): Polysomnographic abnormalities in schizophrenia: A replication. Biol Psychiat 39: 552–553
Maixner S, Tandon R, Eiser A, Taylor SF, DeQuardo JR, Shipley J . (1998): Effects of antipsychotic treatment on polysomnographic measures in schizophrenia: A replication and extension. Am J Psychiat 155: 1600–1602
Manos N, Gkiouzepas J, Tzotzoras T, Tzanetoglou A . (1981): Gradual withdrawal of antiparkinson medication in schizophrenics: Any better than the abrupt? J Nerv Ment Dis 169: 659–661
Meltzer HY . (1989): Clinical studies on the mechanism of action of clozapine: The dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology 99 Suppl: S18–S27
Meltzer HY, Chai BL, Thompson PA, Yamamoto BK . (1994): Effect of scopolamine on the efflux of dopamine and its metabolites after clozapine, haloperidol or thioridazine. J Pharm Exp Ther 268: 1452–1461
Mesulam M-M, Volicer L, Marquis JK, Mufson EJ, Green RC . (1986): Systematic regional differences in the cholinergic innervation of the primate cerebral cortex: Distribution of enzyme activities and some behavioral implications. Ann Neurol 19: 144–151
Modell JG, Tandon R, Beresford T . (1989): Dopaminergic activity of the “antimuscarinic” antiparkinsonian agents. J Clin Psychopharmacol 9: 347–351
Modestin J, Schwartz RB, Hunger J . (1973): Zur frage beeinflussung schizophrener symptome durch physostigmin. Pharmakopsychiatr Neuropsychopharmakol 6: 300–304
Moore H, Fadel J, Sarter M, Bruno JP . (1998): Role of accumbens and cortical dopamine receptors in the regulation of cortical acetylcholine release. Neuroscience 58: 811–822
Ogren SO . (1992): Pharmacology of atypical neuroleptic drugs: Relevance for muscarinic mechanisms in schizophrenia. Scientific Proceedings of the American College of Neuropsychopharmacology Annual Meeting, San Juan, Puerto Rico
Olianas MC, Maullu C, Onali P . (1997): Effects of clozapine on rat striatal muscarinic receptors coupled to inhibition of adenylyl cyclase activity and on the human cloned m4 receptor. Br J Pharmacol 122: 401–408
Overall JE, Gorham DR . (1962): The Brief Psychiatric Rating Scale. Psycholog Rept 10: 799–812
Palacios JM, Bolliger G, Closse A, Enz A, Gmelin G, Malanowski J . (1986): The pharmacological assessment of RS 86 (2-ethyl-8-methyl-2,8-diazaspiro-[4,5]-decan-1,3-dion hydrobromide): A potent, specific muscarinic acetylcholine receptor agonist. Eur J Pharmacol 125: 45–62
Parada MA, Parada MPD, Hernandez L, Garcia F, Murzi E, Conperas Q . (1998): Clozapine-induced acetylcholine release in the rat prefrontal cortex, nucleus accumbens, and striatum does not develop tolerance. Prog Neuro-Psychopharmacol Biol Psychiat 22: 1379–1397
Pfeiffer CC, Jenney EH . (1957): Inhibition of the conditioned response and the counteraction of schizophrenia by muscarinic stimulation of the brain. Ann NY Acad Sci 66: 753–764
Pickar D, Breier A, Hsiao JK, Doran AR, Wolkowitz OM, Pato CN, Konicki PE, Potter WZ . (1990): Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis: Implications for regional brain dysfunction in schizophrenia. Arch Gen Psychiat 47: 641–648
Poland RE, McCracken JT, Lutchmansingh P, Lesser IM, Tondo L, Edwards C, Boone KB, Lin K-M . (1997): Differential response of rapid eye movement sleep to cholinergic blockade by scopolamine in currently depressed, remitted, and normal control subjects. Biol Psychiat 41: 929–938
Rechtschaffen A, Kales A, Berger RJ . (1968): A Manual of Standardized Terminology, Techniques, and Scoring System for Sleep Stages in Human Subjects. Public Health Service, U.S. Government Printing Office, Washington DC
Richelson E . (1984): Neuroleptic affinities for human brain receptors and their use in predicting adverse effects. J Clin Psychiat 45: 331–336
Riemann D, Gann H, Fleckenstein P, Hohagen F, Olbrich R, Berger M . (1994): Effect of RS 86 on REM latency in schizophrenia. Psychiat Res 38: 89–92
Rifkin A, Quitkin F, Kane J, Struve F, Klein DF . (1978): Are prophylactic antiparkinson drugs necessary? A controlled study of procyclidine withdrawal. Arch Gen Psychiat 35: 483–489
Risch SC, Cohen RM, Janowsky DS, Kalin NH, Sitaram N, Gillin JC, Murphy DL . (1981): Physostigmine induction of depressive symptomatology in normal human subjects. Psychiat Res 4: 89–94.
Rivest R, Marsden CA . (1991): Inhibition of apomorphine-induced climbing in mice by cholinergic drugs and clozapine. Br J Pharmacol 104: 234–238
Rowntree DW, Nevin S, Wilson A . (1950): The effects of diisopropylfluorophosphonate in schizophrenia and manic depressive psychosis. J Neurol Neurosurg Psychiat 13: 47–62
Salin-Pascual RJ, Granados-Fuentes D, Galicia-Polo L, Nieves E . (1991): Rapid eye movement (REM) sleep increases by auditory stimulation reverted with biperiden administration in normal volunteers. Neuropsychopharmacology 5: 183–186
Sandyk R, Kay SR . (1990): The relationship of negative schizophrenia to parkinsonism. Int J Neurosci 55: 1–59
Schuberth J, Jenden DJ . (1975): Transport of choline from plasma to cerebrospinal fluid in the rabbit with reference to the origin of choline and to acetylcholine metabolism in brain. Brain Res 84: 245–256
Singh MM, Kay SR . (1979): Therapeutic antagonism between anticholinergic antiparkinsonism agents and neuroleptics in schizophrenia: Implications for a neuropharmacological model. Neuropsychobiology 5: 74–86
Singh MM, Kay SR . Opler LA . (1987): Anticholinergic-neuroleptic antagonism in terms of positive and negative symptoms of schizophrenia: Implications for psychobiological subtyping. Psycholog Med 17: 39–48
Sitaram N, Gillin JC . (1980): Development and use of pharmacological probes of the CNS in man: Evidence of cholinergic abnormality in primary affective illness. Biol Psychiat 15: 925–955
Sitaram N, Moore AM, Gillin JC . (1978): Experimental acceleration and slowing of REM sleep ultradian rhythm by cholinergic agonist and antagonist. Nature 274: 490–492
Spitzer RL, Endicott J . (1979): Schedule for Affective Disorders and Schizophrenia—Lifetime Version (SADS-L), 3rd ed. New York: New York State Psychiatric Institute
Spitzer RL, Endicott J, Robins E . (1978): Research Diagnostic Criteria (RDC): Rationale and reliability. Arch Gen Psychiat 35: 773–782
Sumiyoshi T, Hasegawa M, Jayathilake K, Meltzer HY . (1997): Prediction of short-term changes in symptom severity by baseline plasma homovanillic acid levels in schizophrenic patients receiving clozapine. Psychiat Res 69: 113–121
Syvalahti EKG, Lauren L, Markannen J, Kunelius R . (1987): Interaction of psychotropic drugs with brain muscarinic cholinoceptors: Similarities of biperiden with pirenzipine in receptor binding properties. Pharmacol Toxicol 60: 66–69
Tandon R . (1997): Effects of atypical antipsychotics on polysomnographic measures in schizophrenia. Bibliog Psychiat 167: 219–222
Tandon R . (1999): Cholinergic aspects of schizophrenia. Br J Psychiat Suppl 173: 7–11
Tandon R, Greden JF . (1989): Cholinergic hyperactivity and negative schizophrenic symptoms: A model of dopaminergic/cholinergic interactions in schizophrenia. Arch Gen Psychiat 46: 745–753
Tandon R, Greden JF . (1991): Cholinergic excess and the negative schizophrenic syndrome. In Greden JF, Tandon R (eds), Negative Schizophrenic Symptoms: Pathophysiology and Clinical Implications. Washington DC: American Psychiatric Press, pp 99–111
Tandon R, Kane JM . (1993): Neuropharmacologic basis for clozapine's unique profile. Arch Gen Psychiat 50: 157–159
Tandon R, Greden JF, Silk KR . (1988): Treatment of negative schizophrenic symptoms with trihexyphenidyl. J Clin Psychopharmacol 8: 212–215
Tandon R, Goldman R, Goodson J, Greden JF . (1990a): Mutability and relationship between positive and negative symptoms during neuroleptic treatment in schizophrenia. Biol Psychiat 27: 1323–1326
Tandon R, Mann N, Eisner W, Coppard N . (1990b): Effect of anticholinergic medication on positive and negative symptoms in medication-free schizophrenic patients. Psychiat Res 31: 235–241
Tandon R, Mazzara C, DeQuardo J, Craig KA, Meador-Woodruff JH, Goldman R, Greden JF . (1991a): Dexamethasone suppression test in schizophrenia: Relationship to symptomatology, ventricular enlargement, and outcome. Biol Psychiat 29: 953–964
Tandon R, Greden JF, Goodson J, Shipley JE, Mann N, Eisner W . (1991b): Muscarinic cholinergic hyperactivity in schizophrenia: Relationship to positive and negative symptoms. Schizoph Res 4: 23–30
Tandon R, DeQuardo JR, Goodson J, Mann NA, Greden JF . (1992a): Effect of anticholinergics on positive and negative symptoms in schizophrenia. Psychopharm Bull 28: 297–302
Tandon R, Shipley JE, Taylor S, Greden JF, Eiser A, DeQuardo JR, Goodson J . (1992b): Electroencephalographic sleep abnormalities in schizophrenia: Relationship to positive/negative symptoms and prior neuroleptic treatment. Arch Gen Psychiat 49: 185–194
Tandon R, Greden JF, Haskett RF . (1993): Cholinergic hyperactivity and negative symptoms: Behavioral effects of physostigmine in normal controls. Schizophr Res 9: 19–23
Tandon R, Lewis C, Taylor SF, Shipley JE, DeQuardo JR, Jibson M, Goldman M . (1996): Relationship between DST nonsuppression and shortened REM latency in schizophrenia. Biol Psychiat 40: 660–663
Taylor SF, Tandon R, Shipley JE, Eiser AS . (1991): Effect of neuroleptic treatment on polysomnographic measures in schizophrenia. Biol Psychiat 30: 904–912
van Kammen DP, Peters J, Yao J, van Kammen WB, Neylan T, Shaw D, Linnoila M . (1990): Norepinephrine in acute exacerbations of chronic schizophrenia: Negative symptoms revisited. Arch Gen Psychiat 47: 161–168
Vance MA, Blumberg JB . (1983): Cholinergic potentiation of neuroleptic effects in the nucleus accumbens. Res Commun Chem Pathol Pharmacol 40: 345–348
Wells BG, Marken PA, Rickman LA, Brown CS, Hamann G, Grimmig J . (1989): Characterizing anticholinergic abuse in community mental health. J Clin Psychopharmacol 9: 431–435
Zeng XP, Le F, Richelson E . (1997): Muscarinic m4 receptor activation by some atypical antipsychotic drugs. Eur J Pharmacol 321: 349–354
Zorn SH, Jones SB, Ward KM, Liston DR . (1994): Clozapine is a potent and selective muscarinic M4 receptor agonist. Eur J Pharmacol 269: R1–2
Acknowledgements
This work was supported by ADAMHA MH 19634-01 and by grants from the Clinical Research Center (NIH Grant MO1 RR 00042), the National Alliance for Research in Schizophrenia and Affective Disorders (NARSAD), the Scottish Rite Schizophrenia Research Foundation and by an unrestricted educational grant from Hoechst Marion Roussel.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tandon, R., Taylor, S., DeQuardo, J. et al. The Cholinergic System in Schizophrenia Reconsidered: Anticholinergic Modulation of Sleep and Symptom Profiles. Neuropsychopharmacol 21 (Suppl 2), S189–S202 (1999). https://doi.org/10.1016/S0893-133X(99)00103-7
Received:
Accepted:
Issue date:
DOI: https://doi.org/10.1016/S0893-133X(99)00103-7
Keywords
This article is cited by
-
Microstructural imaging and transcriptomics of the basal forebrain in first-episode psychosis
Translational Psychiatry (2022)
-
Detailed Cognitive Function and Use of Drugs with Anticholinergic Properties in Older People
Drugs & Aging (2013)
-
Cholinergic mechanisms in schizophrenia: Current concepts
Current Psychosis & Therapeutics Reports (2006)
-
Pharmacologic treatment of schizophrenia: Current status and future trends
Current Psychosis & Therapeutics Reports (2006)
-
Safety and tolerability: How do second-generation atypical antipsychotics compare?
Current Psychosis & Therapeutics Reports (2003)
